Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
Phase 2 Completed
60 enrolled 9 charts
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Phase 2 Completed
11 enrolled 12 charts
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
Phase 2 Completed
1,034 enrolled
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 2 Completed
115 enrolled 12 charts
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Phase 2 Withdrawn
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Phase 2 Withdrawn
LAL0904
Phase 2 Completed
470 enrolled 10 charts
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
Phase 2 Completed
63 enrolled 6 charts
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
Phase 2 Completed
175 enrolled 9 charts
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
Phase 2 Completed
43 enrolled 11 charts
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
111 enrolled 7 charts
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Terminated
1 enrolled 4 charts
Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia
Phase 2 Completed
48 enrolled
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 2 Completed
106 enrolled 6 charts
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
Phase 2 Completed
36 enrolled
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
Phase 2 Completed
120 enrolled
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 2 Unknown
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
60 enrolled
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
Phase 2 Completed
40 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
Phase 2 Completed
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
35 enrolled
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 2 Terminated
13 enrolled
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Phase 2 Completed
53 enrolled
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
106 enrolled
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
Phase 2 Completed
31 enrolled
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
Phase 2 Unknown
60 enrolled